Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity

@article{Cui2012GeneticallyDS,
  title={Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity},
  author={Yunfeng Cui and Jacqueline A. Brosnan and Amanda L. Blackford and Surojit Sur and Ralph H. Hruban and Kenneth W. Kinzler and Bert Vogelstein and Anirban Maitra and Luis A Diaz and Christine A. Iacobuzio-Donahue and James R. Eshleman},
  journal={Clinical Cancer Research},
  year={2012},
  volume={18},
  pages={6519 - 6530}
}
Purpose: Pancreatic cancer is the fourth cause of death from cancer in the western world. Majority of patients present with advanced unresectable disease responding poorly to most chemotherapeutic agents. Chemotherapy for pancreatic cancer might be improved by adjusting it to individual genetic profiles. We attempt to identify genetic predictors of chemosensitivity to broad classes of anticancer drugs. Experimental Design: Using a panel of genetically defined human pancreatic cancer cell lines… Expand
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
TLDR
This work examines extrinsic elements to intrinsic processes within the cell that are important for therapeutic efficacy and resistance in PDA cells and discusses resistance mechanisms that will most likely play a role in the management of this deadly disease. Expand
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors
TLDR
A mechanistic relationship between chemoresistance and metastatic potential in pancreatic carcinoma is suggested and evidence for molecular pathways that may be exploited to develop therapeutic strategies for refractory pancreatic cancer is provided. Expand
Predictive biomarkers for chemotherapies in pancreatic cancer
TLDR
This paper discusses available predictor biomarkers with focus upon gemcitabine and FOLFIRINOX chemotherapy regimens, present approaches in advanced pancreatic cancer. Expand
Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
TLDR
Initial preclinical evidence is provided for an essential role of MYC–ERCC3 interactions in PDAC, and a new mechanistic approach for disruption of critical survival signaling in MYC-dependent cancers is suggested. Expand
Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
TLDR
Other aspects of an individualized approach concerning the main factors for the choice of the best therapy for individual pancreatic cancer patient (surgery and chemotherapy), as well as the future directions (target therapy and immunotherapy), are addressed. Expand
Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma.
TLDR
Using an efficient strategy, transcriptomic analysis could predict the sensitivity to anticancer drugs and the clinical outcome of patients with PDAC and was able to discriminate between patients with long- and short-term survival corresponding to patients with moderately or poorly differentiated PDAC tumors. Expand
Taxanes: impact on pancreatic cancer
TLDR
The combination of nab-paclitaxel and gemcitabine demonstrated significant survival benefit with good tolerability in metastatic pancreatic cancer in the phase III trial MPACT, and now represents one of the gold-standard regimens for this disease. Expand
Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
TLDR
The first evidence indicating that avian IAVs of low pathogenicity display a tropism for human PDA cells is provided, resulting in viral RNA replication and a potent induction of apoptosis in vitro and antitumor effects in vivo. Expand
Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures
TLDR
Novel Hsp90 inhibitors can be developed as antipancreatic cancer agents because their chemical structures are simpler, and they are likely to exhibit lower side effects than the much more complex inhibitors used as controls. Expand
Pancreatic cancer genomics: insights and opportunities for clinical translation
TLDR
Current knowledge of the genetics and genomics of pancreatic cancer from its inception to metastatic colonization is summarized and examples of how this information can be translated into the clinical setting for therapeutic benefit and personalized medicine are provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy
TLDR
Three PDA subtypes are defined: classical, quasimesenchymal and exocrine-like, and evidence for clinical outcome and therapeutic response differences between them is presented, and gene signatures for these subtypes that may have utility in stratifying patients for treatment are defined. Expand
Stromal biology and therapy in pancreatic cancer
TLDR
Stromal cells contained within the PDA tumour microenvironment represent an additional constituent to neoplastic cells that should be critically evaluated for optimal therapeutic development in preclinical models and early clinical trials. Expand
Pancreatic Cancer: From Bench to 5-Year Survival
TLDR
Translational research combined with clinical trials will hopefully lead to improved survival and better quality of life for pancreatic cancer patients in the future. Expand
Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.
TLDR
A cDNA microarray representing 23,040 genes was used to analyze expression profiles in a panel of 85 cancer xenografts derived from nine human organs, identifying 1,578 genes whose expression levels correlated significantly with chemosensitivity. Expand
5‐Fluorouracil or gemcitabine combined with adenoviral‐mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc‐1 pancreatic adenocarcinoma cells
TLDR
Whether combining Ad‐mediated delivery of p53 or p16INK4A with clinically relevant chemotherapeutic drugs has therapeutic potential for pancreatic cancer is examined. Expand
Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70.
TLDR
Triptolide is a potential therapeutic agent that can be used to prevent the progression and metastases of pancreatic cancer and its mechanism of action is mediated via the inhibition of HSP70. Expand
High-Throughput Drug Screening of the DPC4 Tumor-Suppressor Pathway in Human Pancreatic Cancer Cells
TLDR
The results confirm the feasibility of a specific high-throughput reporter system to screen a large compound library in human cells efficiently and identify agents that conferred robust augmentation of the DPC4 signal transduction pathway. Expand
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
TLDR
The current and future applications of pharmacogenomics in clinical cancer therapy and cancer drug development are discussed. Expand
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
TLDR
Pancreatic cancers are represented by distinct genetic subtypes with significantly different patterns of failure, and determinations of DPC4 status at initial diagnosis may be of value in stratifying patients into treatment regimens related to local control versus systemic therapy. Expand
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
TLDR
It is found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations, which defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors. Expand
...
1
2
3
4
5
...